Population pharmacokinetics of arbekacin in burn patients
- 5 March 2008
- journal article
- pharmacokinetics and-disposition
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 64 (6), 599-603
- https://doi.org/10.1007/s00228-008-0470-1
Abstract
The aim of this study was to estimate the pharmacokinetics (PK) of arbekacin in burn patients using a population–PK approach. Therapeutic drug monitoring data consisting of 126 plasma concentrations (including 17 values that were below the quantitation limit) from 47 burn patients were retrospectively analyzed using a mixed effect method (NONMEM, ver. 6.0). Covariates, such as burn index, age, sex, among others, were tested on the basic one-compartment model. In the basic model, positive correlations of body weight (WT) and creatinine clearance (CLcr) on total clearance (CL) and volume of distributions (V) were assumed. In the final model, V increased with burn index (BI). The final model was: \( CL{\left( {L \mathord{\left/ {\vphantom {L h}} \right. \kern-\nulldelimiterspace} h} \right)} = 3.18x{WT} \mathord{\left/ {\vphantom {{WT} {70}}} \right. \kern-\nulldelimiterspace} {70} + 4.49x{CLcr} \mathord{\left/ {\vphantom {{CLcr} {120}}} \right. \kern-\nulldelimiterspace} {120} \);\( V{\left( L \right)} = 27.5x{WT} \mathord{\left/ {\vphantom {{WT} {70}}} \right. \kern-\nulldelimiterspace} {70} + 0.28x{\left( {BI - 23.5} \right)} \). Between-subject variability in terms of CL and V were 35 and 39%, respectively. The CL of our burn patients was significantly greater than that reported in unburned patients, and V increased proportionally with increasing BI.
Keywords
This publication has 13 references indexed in Scilit:
- Population Pharmacokinetics of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2006
- Artificial neural network modeling to predict the plasma concentration of aminoglycosides in burn patientsBiomedicine & Pharmacotherapy, 2004
- Pharmacokinetics of antibiotics in burn patientsJournal of Antimicrobial Chemotherapy, 1999
- The Importance of Antibiotic Pharmacokinetics in Critical IllnessThe American Journal of Surgery, 1996
- Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureusJournal of Antimicrobial Chemotherapy, 1995
- Pharmacokinetics of Systemically Administered Antibiotics in Patients with Thermal InjuryClinical Infectious Diseases, 1992
- Vancomycin pharmacokinetics in burn patients and intravenous drug abusersAntimicrobial Agents and Chemotherapy, 1990
- INCREASED BURN PATIENT SURVIVAL WITH INDIVIDUALIZED DOSAGES OF GENTAMICIN1982
- INCREASED DOSAGE REQUIREMENTS OF GENTAMICIN IN BURN PATIENTSJournal Of Trauma-Injury Infection and Critical Care, 1976
- Experience in Monitoring Gentamicin Therapy during Treatment of Serious Gram-Negative SepsisBMJ, 1974